Data on the effects of Charcot-Marie-Tooth disease type 2N-associated AARS missense mutation (Arg329-to-His) on the cell biological properties.

AARS CMT2 CMT2N Cell biological property Disease-associated mutation

Journal

Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 10 12 2018
revised: 28 03 2019
accepted: 14 05 2019
entrez: 14 6 2019
pubmed: 14 6 2019
medline: 14 6 2019
Statut: epublish

Résumé

Charcot-Marie-Tooth (CMT) diseases are genetic neuropathies in the peripheral nervous system (PNS). Type 1 CMT diseases are neuropathies in Schwann cells, PNS myelinating glial cells, whereas type 2 CMT diseases are axonal neuropathies. In addition, there are other types of categories in CMT diseases. CMT diseases are associated with approximately 100 responsible genes. Taiwanese mutation (Asn71-to-Tyr) of alanyl-tRNA synthetase (AARS) in type 2N CMT disease has been reported to have several pathological effects on properties of AARS proteins themselves [1]. Also, some mutations in other responsible genes affect cell biological properties of their gene products [2,3]. Herein we provide the data regarding the effects of another type 2N CMT disease-associated AARS mutation (Arg329-to-His) in French family on the cellular properties.

Identifiants

pubmed: 31194127
doi: 10.1016/j.dib.2019.104029
pii: S2352-3409(19)30382-8
pii: 104029
pmc: PMC6554220
doi:

Types de publication

Journal Article

Langues

eng

Pagination

104029

Références

Sci Adv. 2018 Apr 04;4(4):eaar4471
pubmed: 29740613
Am J Hum Genet. 2010 Jan;86(1):77-82
pubmed: 20045102
Curr Opin Neurol. 2016 Oct;29(5):537-48
pubmed: 27584852
Neurosci Res. 2019 Feb;139:69-78
pubmed: 30261202
Glia. 2006 Sep;54(4):243-57
pubmed: 16856148
PLoS One. 2011;6(12):e29393
pubmed: 22206013

Auteurs

Naoko Imaizumi (N)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Yu Takeuchi (Y)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Haruka Hirano (H)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Tomohiro Torii (T)

Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.

Yoichi Seki (Y)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Takako Morimoto (T)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Yuki Miyamoto (Y)

Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo 157-8535, Japan.

Hiroyuki Sakagami (H)

Department of Anatomy, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0734, Japan.

Junji Yamauchi (J)

Laboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.
Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo 157-8535, Japan.

Classifications MeSH